OBJECTIVES The aim of this study was to compare outcomes of alcohol septal ablation (ASA) in young and elderly patients with obstructive hypertrophic cardiomyopathy (HCM).
I f patients with obstructive hypertrophic cardiomyopathy (HCM) remain severely symptomatic despite optimal medical therapy, septal reduction therapy should be considered. This can be done either by surgical myectomy or alcohol septal ablation (ASA) (1, 2) . ASA was introduced as a percutaneous alternative to surgical myectomy and has been shown to be effective in reducing left ventricular outflow tract (LVOT) obstruction and associated symptoms in the 20 years since (3) (4) (5) . Concerns about ASA remain, however, especially about the possible arrhythmogenic effect of the ablation scar in patients who are already at an increased risk of life-threatening arrhythmias (6) . The American College of Cardiology Foundation/ American Heart Association guidelines on HCM state that ASA should be reserved for elderly patients and patients with serious comorbidities (1) . Little is known about the differences in outcome of the procedure between young and elderly patients. The aim of this study was to compare complication rates, symptom relief, and long-term outcomes of ASA in young and elderly patients. The choice of ASA instead of surgical myectomy was made on the basis of patient profile (age, comorbidities, and so on) and patient preference. ASA was performed as described previously (7, 8) . All patients gave informed consent prior to the procedure. Local institutional review board approval was obtained.
Patients were divided into groups by age: #55 and >55 years. The cutoff of 55 years was chosen because this was the median age of the study population (range 18 to 80 years). For the long-term outcomes, 2 control groups were selected from a cohort of 349 nonobstructive HCM patients, also used as the control group in a previous analysis (9 Amount of alcohol, ml
Values are n (%), mean AE SD, or median (interquartile range).
ASA ¼ alcohol septal ablation; EF ¼ ejection fraction; LVOT ¼ left ventricular outflow tract; LVWT ¼ left ventricular wall thickness; NYHA ¼ New York Heart Association; SCD ¼ sudden cardiac death. Values are n (%) or mean AE SD.
ICD ¼ internal cardioverter defibrillator; other abbreviations as in Table 1 . cedural mortality rate is reported to be <1% for myectomy versus up to 4% for ASA (1, (12) (13) (14) . Larger, more recent ASA studies have shown rates of 0.3% to 0.6%, however (15, 16) . Also, a recent meta-analysis comparing ASA to myectomy showed similarly low periprocedural and long-term mortality rates (17) .
Furthermore, subsequent to the publication of the 2011 guidelines, the post-ASA prognosis was demonstrated to be comparable with the sex-and agematched population (15, 16, 18) and with matched post-myectomy patients (18). Notably, these and other studies (15, 16, 19) showed that age was the only independent predictor of mortality following ASA, implying that survival in patients after ASA is not determined by ASA, but by HCM itself.
One of the main concerns about ASA in younger patients is the potential arrhythmogenic effect of the ablation scar in patients who are already at an increased risk of life-threatening arrhythmias (6) .
Recent studies have shown, however, that the longterm risk of SCD after ASA is low and comparable to patients who undergo myectomy (9, 17, 18) . This study showed an annual AAE rate following ASA of 0.7%/ year in the young patients, which was similar to agematched nonobstructive HCM patients and one-half the rate of elderly patients. Outcome of ASA in the Young and the Elderly Another conceivable reason to choose myectomy instead of ASA in younger patients is the >2Â higher risk of atrioventricular block requiring pacemaker implantation following ASA (17, 20) . This higher need for pacemaker implantation may at least partly be explained by the higher age of the patients undergoing ASA: the ASA patients from both meta-analyses were on average 9 years older than the myectomy patients. The present and previous studies have shown that atrioventricular conduction disturbances following ASA are mainly seen in elderly patients (10, 21) , with a need for pacemaker implantation in only 5% of the young patients, despite a higher amount of alcohol use in the young patients. Large outcome studies following myectomy in HCM patients of similar age categories (mean age 37 to 47 years) showed incidences of atrioventricular block requiring pacemaker implantation of 1% to 6% (12, 13, 22, 23) .
Because the improvement in functional status following ASA in young and elderly patients is similarly good, we propose that the indication for ASA can be broadened to younger patients. In other words, younger age alone should not be a reason to exclude ASA. For children and adolescents, however, little to no results are available following ASA, although there is substantial experience with myectomy (24) . We therefore recommend against ASA in this age group until studies have proven the safety and efficacy of the procedure in these very young patients.
PATIENT SELECTION AND SPECIALIZED CARE. In line with the 2011 American College of Cardiology (1) and the 2014 European Society of Cardiology (2) guidelines, we recommend that all patients consid- STUDY LIMITATIONS. There were significant differences in baseline characteristics between the young and elderly patients who underwent ASA. Besides the expected differences in prevalence of systolic dysfunction and coronary artery disease, we noted higher amounts of alcohol use in the age #55 years population. The same also held true in a recent study comparing the use of low (#2 ml) versus high (>2 ml) doses of alcohol for ASA (25) . In this study of the same patient population as the present study, patients from the high-dose group were significantly younger than those from the low-dose group. Although the 2 groups did not differ in maximal LVWT or LVOT gradient, the patients from the high-dose group did have larger target septal perforator(s), which might explain the difference.
This study has several other limitations. The study was performed in tertiary referral centers for Values are mean AE SD or n (%). Abbreviations as in Table 3 . WHAT IS NEW? We found that ASA is similarly effective for reduction of symptoms in young and elderly patients and that the long-term mortality rate and risk of AAEs following ASA in young and elderly patients is comparable to age-matched nonobstructive HCM patients.
WHAT IS NEXT? We propose that the indication for ASA can be broadened to younger patients. However, more studies with long-term follow-up of young HCM patients undergoing ASA are warranted to confirm these findings.
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